Back grey_arrow_rt.gif
 
Archived NATAP Articles from May 2002
 
null.gif
 
 
  1. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (HIV negative) - (05/31/02)

    2.  
  2. Interferon alfa-2b plus Ribavirin for HCV-infected Patients with Normal ALT - (5/28/02)

    3.  
  3. IMPACT OF HIGH SERUM GLUCOSE ON LIVER FIBROSIS IN CHRONIC HEPATITIS C - (5/24/02)

    4.  
  4. HCV/HIV Coinfection at DDW Liver Conference - (5/24/02)

    5.  
  5. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C - (05/23/02)

    6.  
  6. THE IMPACT OF ALCOHOL AND INTERFERON TREATMENT ON THE CLINICAL OUTCOME OF HEPATITIS C (HCV)-RELATED CIRRHOSIS - (05/23/02)

    7.  
  7. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels - (05/23/02)

    8.  
  8. Fatigue, HCV/HIV Coinfection, Transmission, Disease Progression & Interferon Written by David Bernstein, MD, Chief of Hepatology at North Shore Hospital, Manhasset, NY - (5/23/02)

    9.  
  9. HCV /HIV Nonresponders Experience Improved Disease Progression - (5/23/02)

    10.  
  10. PEGINTERFERON ALPHA-2A ALONE OR IN COMBINATION WITH RIBAVIRIN ENHANCES RESTORATION OF THE HCV SPECIFIC T CELL RESPONSES IN PATIENTS WITH CHRONIC HEPATITIS C - (5/23/02)

    11.  
  11. BONE LOSS in HCV - (5/23/02)

    12.  
  12. HEPATITIS C - TRANSMISSION BY TOOTHBRUSHES: A MYTH OR A REAL POSSIBILITY? - (5/22/02)

    13.  
  13. GILEAD ANNOUNCES INITIATION OF NIH-SPONSORED PHASE I TRIAL TO EVALUATE TENOFOVIR TOPICAL GEL AS PREVENTIVE FOR VAGINAL TRANSMISSION OF HIV - (05/22/02)

    14.  
  14. ROCHE AND TRIMERIS ANNOUNCE 24-WEEK RESULTS FROM SECOND PIVOTAL STUDY OF HIV FUSION INHIBITOR T-20 - (05/21/02)

    15.  
  15. BRISTOL-MYERS SQUIBB ANNOUNCES EARLY ACCESS PROGRAM TO PROVIDE EXPERIMENTAL PROTEASE INHIBITOR ATAZANAVIR TO PATIENTS WITH HIV - (05/21/02)

    16.  
  16. Key Selected Highlights From Day One Hepatitis C Oral Presentations - (5/21/02)

    17.  
  17. Pegylated Interferon (PegIntron) and Ribavirin for Hep C Patients who were Previous Nonresponders - (5-21-02)

    18.  
  18. Prediction of Early Virologic Response to Pegasys plus Ribavirin in Patients with Genotype 1: can 24 hour viral load response predict 72 week outcome - (5/21/02)

    19.  
  19. PegIntron and Ribavirin in African-Americans and Caucasians; preliminary report - (5/21/02)

    20.  
  20. HCV Therapy in Methadone Maintenance - (5/21/02)

    21.  
  21. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection - (05/14/02)

    22.  
  22. Letter From Bristol Myers Squibb About DDI and Tenofovir Interaction - (05/13/02)

    23.  
  23. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C (with editorial)  PDF - (05/09/02)

    24.  
  24. New study: HCV and racial disparities in response to antiviral therapy - (05/09/02)

    25.  
  25. Gilead Announces Preliminary 48-Week Study Results Showing Viread Comparable to Stavudine in Treatment-Naive HIV Patients - (05/08/02)

    26.  
  26. Lipodystrophy Conference in Marbella, Spain Reported for NATAP by Mike Youle, MD, Royal Free Hospital, London, UK - (05/06/02)

    27.